Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

EXOZ vs BUDA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BUDA Captures Overall Composite Edge (34.2 SELL vs 42.3 HOLD), While EXOZ Leads 3–1 on Growth & Valuation Pillars

BUDA Overall Winner 6-Pillar Tally: EXOZ 3 – 1 BUDA (2 Tie) Matrix Metrics: EXOZ 6 – 1 BUDA

As of Nov 20, 2026, BUDA (BUDA) captures the overall head-to-head institutional edge over eXoZymes Inc. (EXOZ) on higher Unified Composite conviction (34.2/100 SELL vs. 42.3/100 HOLD) after splitting the core matrix 1–6 (led by Options & Positioning), while EXOZ wins 3–1 across the 6-pillar growth and valuation breakdown. EXOZ trades at $2.90 (N/M Forward P/E, 0.0% operating margin) versus BUDA at $5.30 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While EXOZ currently prints a higher short-term Unified Composite Score (42.3/100 HOLD vs. BUDA 34.2/100 SELL), BUDA captures the overall institutional head-to-head verdict (1–6 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (N/A vs. 0.0% operating margin) and revenue trajectory (N/A vs. +0.0% YoY).
  • Technical & Structure Timing Caution: EXOZ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.7); meanwhile BUDA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EXOZ vs BUDA
EXOZ NASDAQ
eXoZymes Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$2.90
-14.05% 1D
Market Cap $31.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.86β · 109% Vol
Unified Composite Score
42.3 / 100 HOLD
Tech 25.0 Fund 51.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.5%), weak momentum, RSI 29
RSI-14: 28.7 · SMA20: $3.96 · SMA50: $4.82
BUDA US Equity Head-to-Head Winner
BUDA
Institutional Equity
$5.30
-0.19% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.03β · 71% Vol
Unified Composite Score
34.2 / 100 SELL
Tech 35.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 28
RSI-14: 28.2 · SMA20: $6.51 · SMA50: $7.15

6-Pillar Scorecard Institutional Category Breakdown (EXOZ 3 – 1 BUDA)

Columns: Metric · EXOZ · BUDA
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale EXOZ
Revenue Growth (YoY) +0.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) N/A N/A
Market Cap $31.9M N/A
3. Profitability & Quality EXOZ
Gross Margin N/A N/A
Operating Margin 0.0% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -187.2% N/A
4. Balance Sheet & Cash Flow EXOZ
Cash Generation (TTM) -$7.1M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.6M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BUDA
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EXOZ (6) vs BUDA (1)
Institutional Metric EXOZ BUDA Criterion Row Edge
Market Capitalization
Scale
$31.9M N/A Larger Scale EXOZ
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% N/A Higher Growth EXOZ
Operating Margin (TTM)
Profitability
0.0% N/A Higher Margin EXOZ
Net Profit Margin
Profitability
0.0% N/A Higher Margin EXOZ
Return on Equity (ROE)
Capital Efficiency
-187.2% N/A Higher ROE EXOZ
52-Week Range Position
Momentum
1% ($3–$17) 1% ($5–$12) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
0.86β · 109% Vol -0.03β · 71% Vol Lower Realized Risk BUDA
Unified Institutional Score
Composite Signal
42.3 / 100 (HOLD) 34.2 / 100 (SELL) Higher Composite EXOZ
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.1M ($4.6M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BUDA +4.61 pp
EXOZ: -25.51% · BUDA: -20.9%
3M Horizon BUDA +17.41 pp
EXOZ: -58.74% · BUDA: -41.33%
6M Horizon BUDA +31.09 pp
EXOZ: -69.1% · BUDA: -38.01%
1Y Horizon BUDA +35.34 pp
EXOZ: -69.99% · BUDA: -34.65%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EXOZ vs BUDA. Trailing 12-month operating profitability (EXOZ 0.0% vs BUDA N/A) and valuation multiples (EXOZ N/M vs BUDA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EXOZ ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-187.2% · N/M
BUDA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EXOZ BREAKDOWN
57d in phase · OBV DISTRIBUTION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact EXOZ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BUDA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BUDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EXOZ Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $31.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BUDA Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EXOZ vs BUDA Key Questions & Quantitative Answers

As of Nov 20, 2026, BUDA (BUDA) captures the overall head-to-head institutional edge over eXoZymes Inc. (EXOZ) on higher Unified Composite conviction (34.2/100 SELL vs. 42.3/100 HOLD) after splitting the core matrix 1–6 (led by Options & Positioning), while EXOZ wins 3–1 across the 6-pillar growth and valuation breakdown. EXOZ trades at $2.90 (N/M Forward P/E, 0.0% operating margin) versus BUDA at $5.30 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While EXOZ currently prints a higher short-term Unified Composite Score (42.3/100 HOLD vs. BUDA 34.2/100 SELL), BUDA captures the overall institutional head-to-head verdict (1–6 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (N/A vs. 0.0% operating margin) and revenue trajectory (N/A vs. +0.0% YoY). Technical & Structure Timing Caution: EXOZ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.7); meanwhile BUDA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EXOZ leads the Growth & Scale pillar: EXOZ posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with BUDA at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, EXOZ generates N/A in USD-normalized revenue versus N/A for BUDA. In operating R&D and SG&A reinvestment, EXOZ deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BUDA.

EXOZ and BUDA trade at balanced relative valuation multiples. EXOZ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas BUDA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EXOZ (-187.2% ROE) versus BUDA (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, EXOZ carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.86β · 109% Vol realized risk). By comparison, BUDA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.03β · 71% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.